Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Mecbotamab Vedotin + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Mecbotamab Vedotin | BA3011|CAB-AXL-ADC|BA-3011|BA 3011 | AXL Antibody 5 | Mecbotamab Vedotin is an antibody-drug conjugate comprising a reversible Axl antibody conjugated to monomethyl auristatin E (MMAE), which delivers the cytotoxic agent to Axl-expressing tumor cells, potentially inducing cytotoxicity and tumor growth inhibition (Cancer Res 2018;78(13 Suppl):Abstract nr 827; Journal of Clinical Oncology 2018 36:15_suppl, TPS12126). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04681131 | Phase II | Mecbotamab Vedotin Mecbotamab Vedotin + unspecified PD-1 antibody | CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC | Active, not recruiting | USA | POL | ITA | GRC | ESP | 2 |